Early diagnosis and treatment of hypercholesterolemia in children as a key to reducing mortality from cardiovascular diseases
- 25 April 2026
- journal article
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 71 (2)
Abstract
Coronary heart disease, which is caused by coronary atherosclerosis, is the largest contributor to cardiovascular mortality. Atherosclerosis originates in childhood. This article presents data on the prevalence and etiology of familial hypercholesterolemia, characterized by high levels of low-density lipoprotein cholesterol. This leads to the onset of atherosclerotic vascular disease in childhood and the development of myocardial infarction in the second or third decade of life. The disease is asymptomatic for a long time, especially in childhood, and therefore its detection rate is less than 1%. Diagnostic criteria and genetic aspects of the disease are outlined, and various screening options for hypercholesterolemia are discussed. A strategy for the primary prevention of cardiovascular disease is presented, and current drug therapy options are discussed. Indications for the use of statins, cholesterol absorption inhibitors, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are presented. It is demonstrated that early detection of familial hypercholesterolemia in children will facilitate the timely initiation of lipid-lowering therapy, which will halt the progression of atherosclerosis and prevent the development of coronary heart disease.Keywords
This publication has 28 references indexed in Scilit:
- Global Burden of Cardiovascular Diseases and Risks, 1990-2022JACC, 2023
- Long-Term Evolocumab in Patients With Familial HypercholesterolemiaJACC, 2020
- Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countriesAtherosclerosis, 2020
- Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of careAtherosclerosis, 2019
- Sitosterinämie (Phytosterinämie)Die Innere Medizin, 2019
- Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature reviewAtherosclerosis, 2018
- Cascade screening for familial hypercholesterolemia: Practical consequencesAtherosclerosis Supplements, 2017
- Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhoodAtherosclerosis, 2015
- Long-Term Statin Treatment in Children with Familial Hypercholesterolemia: More Insight into Tolerability and AdherencePediatric Drugs, 2015
- Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: A study of a cohort of 14,000 mutation carriersAtherosclerosis, 2014